Patent publications are routine IP milestones for a clinical-stage biotech with no near-term revenue. Monitor for future clinical trial initiations or partnership announcements involving these combination candidates.
Price Chart
Executive Summary
Clearmind Medicine announced the U.S. publication of three patent applications covering novel combinations of LSD, ketamine, and ibogaine with N-acylethanolamines (PEA) for potential therapeutic uses in mental health disorders, pain, and substance use disorders. This expands the company's IP portfolio through its collaboration with NeuroThera Labs Inc., but does not represent clinical data, regulatory milestones, or near-term revenue.
Key Facts
- Three U.S. patent applications published covering combinations of LSD, ketamine, and ibogaine with N-acylethanolamines (PEA).
- Applications address potential uses in depression, PTSD, pain, and substance use disorders.
- IP generated through ongoing collaboration with NeuroThera Labs Inc. (TSXV: NTLX).
- Clearmind's portfolio now includes 19 patent families and 32 granted patents.
- No clinical data, regulatory approvals, or financial terms disclosed.
Financial Impact
No financial impact disclosed; patent publications are pre-revenue IP portfolio events.
Risk Factors
- Patent applications may not issue as granted patents or may issue in a narrower form.
- No clinical data yet; therapeutic claims are unproven.
- Company remains pre-revenue with no disclosed near-term commercialization path.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-102371 |
| Document: ea030637501ex99-1.htm | 0001213900-26-102371 |
| Document: 0001213900-26-102371-index-headers.html | 0001213900-26-102371 |
| Document: 0001213900-26-102371-index.html | 0001213900-26-102371 |
| Document: 0001213900-26-102371.txt | 0001213900-26-102371 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.95 (+0.47%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.95 (−8.50%) |
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $5.95 (+0.87%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.95 (−4.53%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.95 (−13.35%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.95 (+530.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers